SCYNEXIS (SCYX) Competitors

SCYNEXIS logo
$1.12 -0.05 (-4.27%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$1.13 +0.01 (+0.89%)
As of 02/14/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYX vs. INBX, ACRV, PRQR, ACRS, IKT, ACTU, SCPH, ALEC, GLSI, and LYEL

Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Inhibrx (INBX), Acrivon Therapeutics (ACRV), ProQR Therapeutics (PRQR), Aclaris Therapeutics (ACRS), Inhibikase Therapeutics (IKT), Actuate Therapeutics (ACTU), scPharmaceuticals (SCPH), Alector (ALEC), Greenwich LifeSciences (GLSI), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.

SCYNEXIS vs.

SCYNEXIS (NASDAQ:SCYX) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.

SCYNEXIS received 474 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 58.49% of users gave Inhibrx an outperform vote.

CompanyUnderperformOutperform
SCYNEXISOutperform Votes
505
70.04%
Underperform Votes
216
29.96%
InhibrxOutperform Votes
31
58.49%
Underperform Votes
22
41.51%

SCYNEXIS has higher revenue and earnings than Inhibrx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SCYNEXIS$140.14M0.30$67.04M-$0.74-1.51
Inhibrx$1.63M118.95-$154.96MN/AN/A

Inhibrx has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. SCYNEXIS's return on equity of -66.21% beat Inhibrx's return on equity.

Company Net Margins Return on Equity Return on Assets
SCYNEXIS-425.41% -66.21% -38.84%
Inhibrx N/A -113.74%-80.56%

In the previous week, Inhibrx had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Inhibrx and 1 mentions for SCYNEXIS. Inhibrx's average media sentiment score of 0.33 beat SCYNEXIS's score of 0.00 indicating that Inhibrx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SCYNEXIS
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 2.9% of SCYNEXIS shares are owned by insiders. Comparatively, 22.2% of Inhibrx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Inhibrx
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

SCYNEXIS beats Inhibrx on 8 of the 14 factors compared between the two stocks.

Get SCYNEXIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCYX vs. The Competition

MetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$42.50M$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-1.519.7126.2219.45
Price / Sales0.30290.45456.5777.34
Price / Cash0.6175.4646.0638.90
Price / Book0.575.537.355.05
Net Income$67.04M$123.46M$3.19B$222.81M
7 Day Performance-5.08%3.13%2.63%1.94%
1 Month PerformanceN/A2.14%3.99%1.48%
1 Year Performance-34.88%1.28%22.11%16.47%

SCYNEXIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCYX
SCYNEXIS
0.558 of 5 stars
$1.12
-4.3%
N/A-34.9%$42.50M$140.14M-1.5160
INBX
Inhibrx
2.2322 of 5 stars
$12.49
-0.9%
N/A-64.5%$180.86M$1.63M0.00166Short Interest ↓
Gap Up
ACRV
Acrivon Therapeutics
2.2283 of 5 stars
$5.63
-6.6%
$23.67
+320.7%
+37.6%$175.16MN/A-2.0858Short Interest ↓
PRQR
ProQR Therapeutics
2.1073 of 5 stars
$2.12
-5.7%
$8.83
+316.5%
+24.1%$173.24M$7.05M-6.63180
ACRS
Aclaris Therapeutics
3.1847 of 5 stars
$2.39
-4.2%
$11.00
+361.2%
+95.8%$170.36M$27.08M-4.59100Upcoming Earnings
Short Interest ↑
Gap Up
IKT
Inhibikase Therapeutics
1.6627 of 5 stars
$2.46
+4.5%
$6.50
+164.8%
-0.4%$170.28M$260,000.00-0.926Analyst Revision
ACTU
Actuate Therapeutics
N/A$8.71
-1.2%
N/AN/A$170.01MN/A0.0010
SCPH
scPharmaceuticals
3.9554 of 5 stars
$3.35
+3.1%
$15.00
+347.6%
-35.9%$167.68M$30.28M-1.7630
ALEC
Alector
3.8642 of 5 stars
$1.67
-4.9%
$3.75
+125.2%
-73.3%$163.05M$97.06M-0.98270
GLSI
Greenwich LifeSciences
1.9292 of 5 stars
$12.30
-0.8%
$38.00
+209.1%
+10.1%$161.68MN/A-15.373Short Interest ↑
Analyst Revision
LYEL
Lyell Immunopharma
2.6629 of 5 stars
$0.55
-3.6%
$1.00
+80.8%
-67.2%$161.56M$130,000.00-0.70270Gap Up

Related Companies and Tools


This page (NASDAQ:SCYX) was last updated on 2/18/2025 by MarketBeat.com Staff
From Our Partners